Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Vaziri ND, Norris KC.

Blood Purif. 2013;35(1-3):31-6. doi: 10.1159/000345176. Epub 2013 Jan 22. Review.

PMID:
23343544
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

PMID:
16973506
[PubMed - indexed for MEDLINE]
Free Article
3.

Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.

Marrs JC, Saseen JJ.

Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823. Review.

PMID:
20653359
[PubMed - indexed for MEDLINE]
4.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID:
16493350
[PubMed - indexed for MEDLINE]
5.

Atherogenic lipoproteins in end-stage renal disease.

Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S30-3. Review.

PMID:
11576918
[PubMed - indexed for MEDLINE]
6.

Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.

Chan DT, Irish AB, Dogra GK, Watts GF.

Atherosclerosis. 2008 Feb;196(2):823-34. Epub 2007 Mar 6. Review.

PMID:
17343861
[PubMed - indexed for MEDLINE]
7.

Management of dyslipidemias in patients with diabetes and chronic kidney disease.

Molitch ME.

Clin J Am Soc Nephrol. 2006 Sep;1(5):1090-9. Epub 2006 Jul 26. Review.

PMID:
17699330
[PubMed - indexed for MEDLINE]
Free Article
8.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
[PubMed - indexed for MEDLINE]
9.

Is lipid management effective for all stages of CKD?.

Ku E, Campese V.

Blood Purif. 2013;35(1-3):26-30. doi: 10.1159/000345932. Epub 2013 Jan 22. Review.

PMID:
23343543
[PubMed - indexed for MEDLINE]
10.

Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.

Vaziri ND.

J Ren Nutr. 2010 Sep;20(5 Suppl):S35-43. doi: 10.1053/j.jrn.2010.05.010. Review.

PMID:
20797569
[PubMed - indexed for MEDLINE]
11.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
[PubMed - indexed for MEDLINE]
12.

[Statins and kidney disease].

Bigazzi R, Grimaldi D, Bianchi S.

G Ital Nefrol. 2012 Mar-Apr;29(2):160-73. Review. Italian.

PMID:
22538946
[PubMed - indexed for MEDLINE]
13.

Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Nitta K.

Clin Exp Nephrol. 2012 Aug;16(4):522-9. doi: 10.1007/s10157-012-0655-x. Epub 2012 Jun 22. Review.

PMID:
22722878
[PubMed - indexed for MEDLINE]
14.

[Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].

Kes P, Reiner Z, Brunetta B.

Lijec Vjesn. 2002 Nov-Dec;124(11-12):372-7. Review. Croatian.

PMID:
12679979
[PubMed - indexed for MEDLINE]
15.

Statins and renal disease: friend or foe?

Deshmukh A, Mehta JL.

Curr Atheroscler Rep. 2011 Feb;13(1):57-63. doi: 10.1007/s11883-010-0140-5. Review.

PMID:
21053107
[PubMed - indexed for MEDLINE]
16.

Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.

Tsimihodimos V, Dounousi E, Siamopoulos KC.

Am J Nephrol. 2008;28(6):958-73. doi: 10.1159/000144024. Epub 2008 Jul 9. Review.

PMID:
18612199
[PubMed - indexed for MEDLINE]
17.

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.

PMID:
16259526
[PubMed - indexed for MEDLINE]
18.

Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.

Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP.

Curr Vasc Pharmacol. 2009 Jul;7(3):264-6. Review.

PMID:
19601850
[PubMed - indexed for MEDLINE]
19.

Is lipid control necessary in hemodialysis patients?

Cheung AK.

Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S95-101. doi: 10.2215/CJN.04780709. Review.

PMID:
19996012
[PubMed - indexed for MEDLINE]
Free Article
20.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk